vir-5500
Generic: Anti-PSMA/CD3 Protease-activated T-cell Engager AMX-500
vir-5500: developed by 1 company · 1 clinical trial tracked.
vir-5500 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect vir-5500 to VIR; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could vir-5500 → VIR affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Hormone-refractory Prostate Cancer
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Vir Biotechnology, Inc. (VIR) Hormone-refractory Prostate Cancer | Phase 1 |
Clinical Trials (1)
A Phase 1, First-in-Human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Participants With Prostate Cancer
Primary endpoint: All parts: Incidence of treatment emergent anti-drug antibodies (ADAs) to VIR-5500
Interventionalopen437 targetStarted 2023-08Completion 2027-0912 sites · Australia, Spain, United Kingdom, United StatesAstellas Pharma Global Development, Inc.
Frequently asked questions
Who is developing vir-5500?
vir-5500 is being developed by Vir Biotechnology, Inc..
How many clinical trials involve vir-5500?
BioSniper tracks 1 clinical trial involving vir-5500.